Protocadherin beta-7 (PCDHB7)

Protocadherin beta-7 (PCDHB7) is a member of the beta cluster of protocadherin genes, a subgroup within the cadherin superfamily, located on chromosome 5[1][4]. The beta protocadherin cluster contains multiple genes encoding neural cadherin-like cell adhesion proteins, each with six extracellular cadherin domains and a cytoplasmic region that diverges from classical cadherins[1][5]. These are single-pass transmembrane proteins predominantly expressed in the nervous system, where they participate in calcium-dependent, homophilic cell-cell adhesion and are believed to play key roles in establishing and maintaining specific neuronal connections[1][6]. Unlike classical cadherins, protocadherins (including PCDHB7) do not have well-defined roles as therapeutic targets, receptors, or enzymes but are implicated in neurodevelopmental processes and possibly in tumor suppression through modulation of cell adhesion and proliferation[6][7]. Mutations or dysregulation of PCDHB7 or its cluster relatives have been associated with neurodevelopmental disorders, such as autism spectrum disorder and Cornelia De Lange syndrome[1], with emerging evidence for potential involvement in some cancer contexts due to their epigenetic silencing[6][7]. There are currently no established drugs targeting PCDHB7 specifically, nor validated clinical biomarkers or documented safety concerns related to it. Key features: - Single-exon, neural-specific, cell adhesion molecule from the cadherin superfamily. - Critical for neural circuit development; probable tumor suppressor-like properties inferred from related family members[7][6]. - Not considered a conventional therapeutic target like a receptor, transporter, or enzyme.

Other names

PCDHB7Protocadherin beta-7PCDH-BETA7PCDH-BETA7 (alternate capitalization)ENSG00000113212 (gene symbol)